Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy

Fertility and Sterility

Volumn 90, Issue 4, 2008, Pages 965-971

  Nanda, Kavita ^a   Amaral, Eliana ^b   Hays, Melissa ^a   Viscola, Marco A M ^b   Mehta, Neha ^a   Bahamondes, Luis ^b  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

antiretroviral therapy; contraception; Depot medroxyprogesterone acetate; HIV; pharmacokinetics

Indexed keywords

EFAVIRENZ; LAMIVUDINE; MEDROXYPROGESTERONE ACETATE; ZIDOVUDINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL; UNIVERSITY HOSPITAL; VIRUS LOAD;

ADULT; ANTI-RETROVIRAL AGENTS; CONTRACEPTIVES, ORAL, SYNTHETIC; DELAYED-ACTION PREPARATIONS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MEDROXYPROGESTERONE 17-ACETATE;

EID: 52949087968     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.07.1348     Document Type: Article

References (23)

1. Kobayashi K., Mimura N., Fujii H., Minami H., Sasaki Y., Shimada N., et al. Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 6 (2000) 3297-3303
2. Brasil Ministério da Saúde. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV. Brasília: Brasil Ministério da Saúde (2006)
3. U.S. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [monograph]. Available at: http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed November 30, 2006.
4. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach [monograph]. April 2002. Available at: http://www.who.int/hiv/topics/arv/scaling_exe_summary.pdf. Accessed November 30, 2006.
5. Gilead Sciences. Tenofovir prescribing information. Available at: http://www.gilead.com/pdf/viread_pi.pdf. Accessed November 30, 2006.
6. Ouellet D., Hsu A., Qian J., Locke C.S., Eason C.J., Cavanaugh J.H., et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol 46 (1998) 111-116
7. Mildvan D., Yarrish R., Marshak A., Hutman H.W., McDonough M., Lamson M., et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr 29 (2002) 471-477
8. Chu J.H., Gange S.J., Anastos K., Minkoff H., Cejtin H., Bacon M., et al. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy. Am J Epidemiol 161 (2005) 881-890
9. Danel C., Moh R., Anzian A., Abo Y., Chenal H., Guehi C., et al. Tolerance and acceptability of an efavirenz-based regimen in 740 adults (predominantly women) in West Africa. J Acquir Immune Defic Syndr 42 (2006) 29-35
10. Halpenny O., Bye A., Cranny A., Feely J., and Daly P.A. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate. Med Oncol Tumor Pharmacother 7 (1990) 241-247
11. Lundgren S., Lonning P.E., Aakvaag A., and Kvinnsland S. Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 27 (1990) 101-105
12. De Souza A., Brechin S., and Penney G. The members' enquiry service: frequently asked questions. J Fam Plann Reprod Health Care 30 (2004) 190-191
13. Scottish Intercollegiate Guidelines Network. Guideline no. 70: diagnosis and management of epilepsy in adults [monograph]. Available at: http://www.sign.ac.uk/guidelines/fulltext/70/index.html. Accessed November 30, 2006.
14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations [monograph]. Available at: http://www.fda.gov/cder/guidance/5356fnl.pdf. Accessed November 30, 2006.
15. da Silveira Rossi A., Fonsechi-Carvasan G.A., Makuch M.Y., Amaral E., and Bahamondes L. Factors associated with reproductive options in HIV-infected women. Contraception 71 (2005) 45-50
16. Reynolds H.W., Janowitz B., Homan R., and Johnson L. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis 33 (2006) 350-356
17. Cohn S.E., Park J.G., Watts D.H., Stek A., Hitti J., Clax P.A., et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 81 (2007) 222-227
18. Ortiz A., Hirol M., Stanczyk F.Z., Goebelsmann U., and Mishell D.R. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA. J Clin Endocrinol Metab 44 (1977) 32-38
19. Shrimanker K., Saxena B.N., and Fotherby K. A radioimmunoassay for serum medroxyprogesterone acetate. J Steroid Biochem 9 (1978) 359-363
20. Karkkainen J., Vesterinen E., Stenman U.H., Adlercreutz H., Nieminen U., and Widholm O. Comparison of mass spectrometry and radioimmunoassay to measure medroxyprogesterone acetate in patients with endometrial cancer. Eur J Cancer 26 (1990) 975-977
21. Fraser I.S., and Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust 1 Suppl 1 (1981) 3-19
22. Pharmacia Limited. Depo-Provera® 150 mg/ml summary of product characteristics. Available at: http://emc.medicines.org.uk/eMC/assets/c/html/DisplayDoc.asp?DocumentID=11121. Accessed November 30, 2006.
23. Gupta C., Osterman J., Santen R., and Bardin C.W. In vivo metabolism of progestins. V. The effect of protocol design on the estimated metabolic clearance rate and volume of distribution of medroxyprogesterone acetate in women. J Clin Endocrinol Metab 48 (1979) 816-820